· Published by Health Canada · Official notice
This is duplicated text of a letter from the Baxter Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 16, 2013
Dear Health Care Professional,
Subject: Detachment of Blue Membrane Disc from Administration Closure (Twist Off Protector) of CLINOLEIC 20% - Lipid Emulsion for Intravenous Nutrition (DIN: 02344327), Product Codes CJDB9501 250 mL, CJDB9503 500 mL, CJDB9504 1000 mL
Baxter Corporation in collaboration with Health Canada is providing you with Important Safety Information regarding the potential for introducing particulate matter into CLINOLEIC 20% while spiking the administration port.
CLINOLEIC 20% is indicated for Parenteral Nutrition (PN) in adults when oral or enteral nutrition is not possible, insufficient, or contraindicated. As a lipid emulsion, CLINOLEIC 20% provides a source of fat (or lipids) for adult patients requiring parenteral nutrition.
Baxter Corporation has recently received product complaints in Canada for full detachment of the sterile blue membrane in CLINOLEIC 20% emulsion after spiking with a transfer or administration set.
According to ASPEN 2004 Guidelines on Safe Practices for Parenteral Nutrition Footnote 1 the use of 1.2 micron in-line filtration for PN formulations with lipids is recommended to remove particulate matter and micro-precipitate contamination. Baxter recommends following the ASPEN Guidelines for PN formulations containing CLINOLEIC 20%. If you are using an administration set without a 1.2 micron filter, it is recommended to add the 2H8603 Clearlink 1.2 micron filter Extension Set or 2C1103 Interlink 1.2 micron filter Extension Set to the set. If you use a non-Baxter administration set without a 1.2 micron filter, please consult the manufacturer for appropriate options to include a 1.2 micron filter.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments.
Any case of serious or unexpected adverse reactions in patients receiving CLINOLEIC 20% should be reported to Baxter Corporation or Health Canada.
Baxter Corporation
7125 Mississauga Rd, Mississauga, Ontario L5N 0C2
1-888-719-9955
canada_productsurveillance@baxter.com
To correct your mailing address or fax number, contact the Baxter Corporation.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636
Sincerely,
Original signed by
Phil Lynch
Director, Quality,
Baxter Corporation
Return to footnote 1 referrer ASPEN (American Society for Parenteral and Enteral Nutrition) Task Force for the Revision of Safe Practices for Parenteral Nutrition. Safe Practices for Parenteral Nutrition. J Parenter Enteral Nutr. 2004: S66
Baxter and Clinoleic are Registered Trademarks of Baxter International Inc. 2013FCA13